Cyclacel Pharmaceuticals Stock Today
| CYCC Stock | USD 0.32 0.02 6.67% |
PerformanceWeak
| Odds Of DistressBelow Average
|
Cyclacel Pharmaceuticals is trading at 0.32 as of the 24th of March 2025, a 6.67 percent increase since the beginning of the trading day. The stock's open price was 0.3. Cyclacel Pharmaceuticals has about a 42 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of May 2004 | Category Healthcare | Classification Health Care |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 205.88 M outstanding shares of which 106.5 K shares are currently shorted by private and institutional investors with about 0.42 trading days to cover. More on Cyclacel Pharmaceuticals
Moving against Cyclacel Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cyclacel Stock Highlights
| CEO Director | Sing Wong | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCyclacel Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cyclacel Pharmaceuticals' financial leverage. It provides some insight into what part of Cyclacel Pharmaceuticals' total assets is financed by creditors.
| |||||
Cyclacel Pharmaceuticals (CYCC) is traded on NASDAQ Exchange in USA. It is located in 200 Connell Drive, Berkeley Heights, NJ, United States, 07922 and employs 10 people. Cyclacel Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.88 M. Cyclacel Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 205.88 M outstanding shares of which 106.5 K shares are currently shorted by private and institutional investors with about 0.42 trading days to cover.
Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cyclacel Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCyclacel Pharmaceuticals holds a total of 205.88 Million outstanding shares. Cyclacel Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 94.58 percent of Cyclacel Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cyclacel Ownership Details
Cyclacel Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 80.0 | |
| Bank Of America Corp | 2024-12-31 | 51.0 | |
| Wells Fargo & Co | 2024-12-31 | 33.0 | |
| Signaturefd, Llc | 2024-12-31 | 20.0 | |
| Harbour Investments, Inc. | 2024-12-31 | 13.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| Mcilrath & Eck, Llc | 2024-12-31 | 0.0 | |
| Qube Research & Technologies | 2024-09-30 | 0.0 | |
| Hrt Financial Llc | 2024-09-30 | 0.0 | |
| Armistice Capital, Llc | 2024-12-31 | 580.5 K | |
| Ubs Group Ag | 2024-12-31 | 47.3 K |
Cyclacel Pharmaceuticals Historical Income Statement
Cyclacel Stock Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share | Quarterly Revenue Growth (0.38) | Return On Assets | Return On Equity |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.